Topical Curcumin-Based Cream Is Equivalent to Dietary Curcumin in a Skin Cancer Model
Figure 2
Curcumin’s effects on AKT/MTOR and ERK pathways in vitro. (a) Western blot of SRB12-p9 tumor cells treated with (+) or without (−) 20 μM curcumin for 24 hours and probed with the indicated antibody. Representative Western blots for two analyzed sets are shown. (b) Band densities of indicated biomarkers () were quantified using ImageQuant software and normalized to actin protein level. Data presented as Mean ± SE. * Indicates versus vehicle-treated control. A significant inhibition of expression of the following biomarkers was observed: pAKT (); pS6 (); p4EBP1 (); pSTAT3 (); pERK1/2 (). a.u.: arbitrary units.
